Mul­ti­ple block­busters from Gilead, Pfiz­er, Ver­tex see (list) price hikes to start 2022

Kick­ing off 2022, hun­dreds of phar­ma­ceu­ti­cals, in­clud­ing some block­busters, saw their list prices rise by about 5% on av­er­age. But over­all, net drug prices (cost af­ter re­bates) de­clined for the fourth year in a row, po­ten­tial­ly com­pli­cat­ing al­ready stalled drug price re­form ef­forts.

Among the drugs see­ing new in­creas­es as of Jan. 1 are Gilead’s bevy of block­buster HIV drugs.

Bik­tarvy, which pulled in more than $7 bil­lion in world­wide sales in 2020, saw a 4.8% price in­crease in 2021, and now, an­oth­er 5.6% in­crease in 2022, ac­cord­ing to a new re­port from the non­prof­it 46brook­lyn Re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.